| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.80▲ | 1.79▲ | 1.81▲ | 1.93▼ | 1.58▲ |
| MA10 | 1.79▲ | 1.82▲ | 1.86▼ | 1.80▲ | 1.51▲ |
| MA20 | 1.79▲ | 1.89▼ | 1.93▼ | 1.63▲ | 1.51▲ |
| MA50 | 1.83▲ | 1.95▼ | 1.83▼ | 1.51▲ | 1.42▲ |
| MA100 | 1.93▼ | 1.77▲ | 1.64▲ | 1.51▲ | 1.47▲ |
| MA200 | 1.90▼ | 1.60▲ | 1.54▲ | 1.41▲ | 1.55▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.008▲ | -0.011▼ | -0.029▼ | 0.032▲ | 0.027▲ |
| RSI | 66.360▲ | 42.652▼ | 45.593▼ | 58.481▲ | 65.661▲ |
| STOCH | 80.556▲ | 19.805▼ | 11.012▼ | 62.906 | 46.336 |
| WILL %R | 0.000▲ | -63.158 | -80.822▼ | -48.187 | -43.005 |
| CCI | 308.475▲ | -40.335 | -84.005 | 42.905 | 286.625▲ |
|
Thursday, November 06, 2025 07:24 AM
NNVC READ THE FULL NNVC RESEARCH REPORT Business Update Mpox Trial to Initiate in Late 2025/Early 2026 NanoViricides, Inc. (NYSE:NNVC) is planning to initiate a Phase 2 clinical trial for the ...
|
|
Wednesday, November 05, 2025 07:23 AM
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan ...
|
|
Monday, November 03, 2025 07:22 AM
November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 07/11/25 | 1.88 | 1.88 | 1.76 | 1.83 | 247,123 |
| 06/11/25 | 2.08 | 2.09 | 1.86 | 1.90 | 515,859 |
| 05/11/25 | 1.9544 | 2.2299 | 1.9544 | 1.97 | 786,575 |
| 04/11/25 | 2.04 | 2.1999 | 1.812 | 1.91 | 677,519 |
| 03/11/25 | 1.65 | 2.065 | 1.65 | 2.03 | 869,414 |
| 31/10/25 | 1.72 | 1.7499 | 1.65 | 1.66 | 180,053 |
| 30/10/25 | 1.86 | 1.8678 | 1.65 | 1.70 | 404,751 |
| 29/10/25 | 1.54 | 1.86 | 1.54 | 1.86 | 1,259,514 |
| 28/10/25 | 1.63 | 1.64 | 1.52 | 1.53 | 167,512 |
| 27/10/25 | 1.60 | 1.63 | 1.58 | 1.61 | 344,547 |
|
|
||||
|
|
||||
|
|